290 related articles for article (PubMed ID: 28091414)
1. Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.
Yu MG; Zheng HY
Chin Med J (Engl); 2017 Jan; 130(2):211-218. PubMed ID: 28091414
[TBL] [Abstract][Full Text] [Related]
2. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
3. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
5. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
6. Targeting FLT3 to treat leukemia.
Konig H; Levis M
Expert Opin Ther Targets; 2015 Jan; 19(1):37-54. PubMed ID: 25231999
[TBL] [Abstract][Full Text] [Related]
7. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.
Prescott H; Kantarjian H; Cortes J; Ravandi F
Expert Opin Emerg Drugs; 2011 Sep; 16(3):407-23. PubMed ID: 21417961
[TBL] [Abstract][Full Text] [Related]
8. FLT3 as a therapeutic target in AML: still challenging after all these years.
Kindler T; Lipka DB; Fischer T
Blood; 2010 Dec; 116(24):5089-102. PubMed ID: 20705759
[TBL] [Abstract][Full Text] [Related]
9. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
10. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
Pemmaraju N; Kantarjian H; Ravandi F; Cortes J
Cancer; 2011 Aug; 117(15):3293-304. PubMed ID: 21319142
[TBL] [Abstract][Full Text] [Related]
11. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
Scholl S; Fleischmann M; Schnetzke U; Heidel FH
Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
[TBL] [Abstract][Full Text] [Related]
13. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
[No Abstract] [Full Text] [Related]
14. FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.
Loschi M; Sammut R; Chiche E; Cluzeau T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070902
[TBL] [Abstract][Full Text] [Related]
15. FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.
Grunwald MR; Levis MJ
Semin Hematol; 2015 Jul; 52(3):193-9. PubMed ID: 26111466
[TBL] [Abstract][Full Text] [Related]
16. FLT3 inhibitors in AML: are we there yet?
Sudhindra A; Smith CC
Curr Hematol Malig Rep; 2014 Jun; 9(2):174-85. PubMed ID: 24682858
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
18. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Megías-Vericat JE; Ballesta-López O; Barragán E; Martínez-Cuadrón D; Montesinos P
Blood Rev; 2020 Nov; 44():100675. PubMed ID: 32147087
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in management of acute myeloid leukemia (AML).
Shah M; Agarwal B
Indian J Pediatr; 2008 Aug; 75(8):831-7. PubMed ID: 18769895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
